GPX3 and colorectal cancer: Similarly, it was found that colorectal cancer cells with low GPx3 expression are also more sensitive to chemotherapies such as oxaliplatin and cisplatin, while cells with high GPx3 expression have increased resistance to platinum-based therapy [119].